|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.5 CHF | 0.00% |
|
+4.28% | -3.16% |
| Apr. 25 | Transcript : Santhera Pharmaceuticals Holding AG, 2023 Earnings Call, Apr 25, 2024 | |
| Apr. 25 | Santhera Pharmaceuticals Swings to Profit in FY23; Revenue Grows | MT |
Oct 26 (Reuters) - The U.S. Food and Drug Administration said on Thursday it has approved Santhera Pharmaceuticals' drug to treat Duchenne muscular dystrophy (DMD), a rare muscle-wasting disorder, in patients two years of age and older. (Reporting by Leroy Leo and Khushi Mandowara in Bengaluru; Editing by Maju Samuel)
| 1st Jan change | Capi. | |
|---|---|---|
| -3.16% | 95.7M | |
| +5.31% | 70.44B | |
| +10.97% | 8.94B | |
| -16.83% | 4.75B | |
| +43.48% | 4.5B | |
| +3.20% | 3.85B | |
| +18.82% | 2.38B | |
| -21.36% | 2.34B | |
| -29.67% | 2.2B | |
| +8.38% | 1.96B |
SANTHERA PHARMACEUTICALS HOLDING AG 
